Cargando…
Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers
Triple-negative breast cancers (TNBCs) often have a high Ki-67 proliferation index and respond favorably to neoadjuvant chemotherapy (NACT) with pathologic complete response (pCR) resulting in ~40% of cases. Nevertheless, morbidity/mortality remain high, mostly due to recurrence in patients with res...
Autores principales: | Srivastava, Pooja, Wang, Tiannan, Clark, Beth Z., Yu, Jing, Fine, Jeffrey L., Villatoro, Tatiana M., Carter, Gloria J., Brufsky, Adam M., Gorantla, Vikram C., Huggins-Puhalla, Shannon L., Emens, Leisha A., Basili, Thais, da Silva, Edaise M., Reis-Filho, Jorge S., Bhargava, Rohit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021249/ https://www.ncbi.nlm.nih.gov/pubmed/35444182 http://dx.doi.org/10.1038/s41523-022-00415-z |
Ejemplares similares
-
Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Kim, Kwan Il, et al.
Publicado: (2014) -
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
por: Fasching, Peter A, et al.
Publicado: (2011) -
Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021) -
Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?
por: Ingolf, Juhasz-Böss, et al.
Publicado: (2014) -
To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)